Sepsis and septic shock are complex clinical syndromes resulting from the interaction between microorganisms and the host's immune response. Sepsis is characterized by fever, tachycardia, and tachypnea associated with infection, while severe sepsis involves organ dysfunction, and septic shock is defined by hypotension despite adequate fluid resuscitation. Bacteria, viruses, fungi, and other pathogens can cause these syndromes, with bacteria being the most studied. Gram-negative bacteria, such as *E. coli* and *Pseudomonas aeruginosa*, are common causes, as are Gram-positive bacteria like *Staphylococcus aureus* and *Streptococcus pyogenes*. The pathogenesis involves microbial invasion, exotoxin release, and the host's inflammatory response, leading to systemic inflammation, coagulation abnormalities, and organ dysfunction. Lipopolysaccharide (LPS) from Gram-negative bacteria and endotoxin-like components from Gram-positive bacteria trigger inflammatory responses, leading to vasodilation, hypotension, and multiorgan failure. The immune system's response includes the release of cytokines such as TNF and IL-1, which contribute to the pathophysiology. Sepsis can progress to septic shock, characterized by hypotension, organ dysfunction, and a high mortality rate. The clinical manifestations include fever, tachycardia, tachypnea, and altered mental status, with laboratory findings showing metabolic acidosis, elevated lactate, and coagulopathy. Diagnosis is based on SIRS criteria and suspected infection. Treatment involves early antibiotic administration, source control, and supportive care, including fluid resuscitation, vasopressors, and mechanical ventilation. The use of goal-directed therapy (EGDT) has shown benefits in reducing mortality. However, the role of adjunctive therapies such as vasopressin, corticosteroids, and activated protein C remains controversial. Hyperglycemia is common in sepsis, and tight glucose control may improve outcomes. Sepsis is a leading cause of death in the US, with high mortality rates, especially in septic shock. Mortality is influenced by the host's immune status and the pathogen involved. Recent studies emphasize the importance of early, aggressive treatment and the use of evidence-based bundles to improve outcomes. Despite advances in treatment, sepsis remains a significant clinical challenge with high morbidity and mortality.Sepsis and septic shock are complex clinical syndromes resulting from the interaction between microorganisms and the host's immune response. Sepsis is characterized by fever, tachycardia, and tachypnea associated with infection, while severe sepsis involves organ dysfunction, and septic shock is defined by hypotension despite adequate fluid resuscitation. Bacteria, viruses, fungi, and other pathogens can cause these syndromes, with bacteria being the most studied. Gram-negative bacteria, such as *E. coli* and *Pseudomonas aeruginosa*, are common causes, as are Gram-positive bacteria like *Staphylococcus aureus* and *Streptococcus pyogenes*. The pathogenesis involves microbial invasion, exotoxin release, and the host's inflammatory response, leading to systemic inflammation, coagulation abnormalities, and organ dysfunction. Lipopolysaccharide (LPS) from Gram-negative bacteria and endotoxin-like components from Gram-positive bacteria trigger inflammatory responses, leading to vasodilation, hypotension, and multiorgan failure. The immune system's response includes the release of cytokines such as TNF and IL-1, which contribute to the pathophysiology. Sepsis can progress to septic shock, characterized by hypotension, organ dysfunction, and a high mortality rate. The clinical manifestations include fever, tachycardia, tachypnea, and altered mental status, with laboratory findings showing metabolic acidosis, elevated lactate, and coagulopathy. Diagnosis is based on SIRS criteria and suspected infection. Treatment involves early antibiotic administration, source control, and supportive care, including fluid resuscitation, vasopressors, and mechanical ventilation. The use of goal-directed therapy (EGDT) has shown benefits in reducing mortality. However, the role of adjunctive therapies such as vasopressin, corticosteroids, and activated protein C remains controversial. Hyperglycemia is common in sepsis, and tight glucose control may improve outcomes. Sepsis is a leading cause of death in the US, with high mortality rates, especially in septic shock. Mortality is influenced by the host's immune status and the pathogen involved. Recent studies emphasize the importance of early, aggressive treatment and the use of evidence-based bundles to improve outcomes. Despite advances in treatment, sepsis remains a significant clinical challenge with high morbidity and mortality.